Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

PHASE4CompletedINTERVENTIONAL

Enrollment

231

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

March 10, 2025

Study Completion Date

March 10, 2025

Conditions

Diabetes Mellitus

Interventions

DRUG

DA-2811

DA-2811 Group: DA-2811 + Forxiga placebo

DRUG

Forxiga

Forxiga Group: Forxiga + DA-2811 placebo

Trial Locations (1)

The Catholic University of Korea Bucheon St. Mary's Hospital, Bucheon-si

All Listed Sponsors

lead

Dong-A ST Co., Ltd.

INDUSTRY